Polymerized-Type I Collagen Downregulates Inflammation and Improves Clinical Outcomes in Patients with Symptomatic Knee Osteoarthritis Following Arthroscopic Lavage: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial

Table 3

Laboratory characteristics of the patients.

	Placebo (𝑛=9)			Polymerized-type I collagen (𝑛=10)
	Baseline	3 months	6 months	Baseline	3 months	6 months
Erythrocyte sedimentation rate (mmHg) Mean ± SD	15.5 ± 10.1	19.6 ± 12.9	12.8 ± 10.6	15.5 ± 10.1	11.9 ± 13.1	7.8 ± 6.7
Anti-cyclic citrullinated peptide antibodies (U); mean ± SD	1.8 ± 0.7			4.3 ± 4.8
Median	1.9			2.7
Range	(0.9–3.0)			(0.5–13.4)
Urinary levels of C-terminal crosslinking telopeptide of collagen type II (ng mmol^−1); mean ± SD	281.4 ± 291.5	283.1 ± 245.0	474.4 ± 333.9	214.3 ± 179.9	196.6 ± 167.4	266.6 ± 146.7
Median	160.0	229.3	460.4	171.9	158.9	237.4
Range	(60.1–882.8)	(102.1–896.2)	(64.6–986.0)	(6.9–592.3)	(0.1–505.9)	(91.7–472.0)